Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1088-1092. doi: 10.19723/j.issn.1671-167X.2020.06.016

Previous Articles     Next Articles

Correlation study on anti-Ro52 antibodies frequently co-occur with other myositis-specific and myositis-associated autoantibodies

Yi-ming ZHENG,Hong-jun HAO,Yi-lin LIU,Jing GUO,Ya-wen ZHAO,Wei ZHANG,Yun YUAN()   

  1. Department of Neurology, Peking University First Hospital, Beijing 100034, China
  • Received:2018-11-02 Online:2020-12-18 Published:2020-12-13
  • Contact: Yun YUAN E-mail:yuanyun2002@126.com
  • Supported by:
    Scientific Research Seed Fund of Peking University First Hospital(2018SF033)

RICH HTML

   

PDF (PC)

Abstract:

Objective: Anti-Ro52 antibodies are frequently co-occur with other myositis-specific and myositis-associated autoantibodies, we here to study this phenomenon in Chinese patients suspected with inflammatory myopathies. Methods: In the study, 1 509 patients clinically suspected with inflammatory myopathies were tested for 11 kinds of myositis-specific and myositis-associated autoantibodies (including: anti-Jo-1, PL-7, PL-12, EJ, OJ, Mi-2, SRP, Ku, PM-Scl 75, PM-Scl 100, and Ro52 antibo-dies) by line-blot immunoassay from 2010 to 2016 in Peking University First Hospital. This retrospective study was to analyze these results to reveal the characteristics of anti-Ro52 antibodies co-occuring with other myositis autoantibodies. The data were analyzed using SPSS 17.0 and Graph Pad PRISM for Chi-square test, independent t-test, Pearson’s correlation analysis, and drawing statistical graphs. Significance level was set at P<0.05. Results: The positive rate of anti-Ro52 antibodies was 18.3% (276/1 509 cases), which was the most frequently detected myositis antibodies in our center. 51.8% (143/276) of the patients with anti-Ro52 antibodies were combined with the other myositis antibodies, and the most common co-occurred antibodies were anti-SRP antibodies (18.8%, 52/276), and the second common co-occurred antibodies were anti-Jo-1 antibodies (13.0%, 36/276). Anti-Ro52 antibodies were the most common antibodies that co-occurred in other myositis antibodies positive patients except in anti-OJ antibodies positive group. The co-positive rate with anti-Ro52 antibodies was the lowest in anti-PM-Scl 75 positive group (30.4%, 31/102), and the highest in anti-EJ positive group (80.0%, 12/15). The positive rate of anti-Ro52 antibodies in anti-synthase antibodies (including anti-Jo-1, EJ, OJ, PL-7, and PL-12 antibodies) positive group was 57.3% (75/131), which was significantly higher than that in the other antibodies (including: anti-Mi-2, SRP, Ku, PM-Scl 75, and PM-Scl 100 antibodies) positive group with 35.2% (119/338) (χ2=18.916, P<0.001). The intensity of anti-Jo-1, EJ, and SRP antibodies in the group of the patients that co-occurred with anti-Ro52 antibodies was significantly higher than that in the other group without anti-Ro52 antibodies respectively (P<0.05). The intensity of anti-SRP antibodies was significantly correlated with that of anti-Ro52 antibodies (r=0.44, P=0.001). Conclusion: Anti-Ro52 antibodies were commonly associated with other myositis-specific and myositis-associated autoantibodies, especially with anti-synthase antibodies, and the co-presence of anti-Ro52 antibodies may be correlated with the myositis antibody intensity.

Key words: Autoantibodies, Myositis, Autoimmune diseases

CLC Number: 

  • R593.2

Figure 1

The myositis antibodies in serum samples of 1 509 patients suspected with idiopathic inflammatory myopathies"

Table 1

The frequency of co-positive of myositis antibodies n (%)"

Antibodies Jo-1 EJ OJ PL-7 PL-12 SRP Mi-2 Ku PM-Scl 75 PM-Scl 100 Ro52
Jo-1 (n=61) - 1 (1.6) 2 (3.3) 0 0 6 (9.8) 4 (6.6) 1 (1.6) 6 (9.8) 1 (1.6) 36 (59.0)
EJ (n=15) 1 (6.7) - 1 (6.7) 1 (6.7) 2 (13.3) 2 (13.3) 1 (6.7) 2 (13.3) 2 (13.3) 1 (6.7) 12 (80.0)
OJ (n=12) 2 (16.7) 1 (8.3) - 0 1 (8.3) 3 (25.0) 2 (16.7) 1 (8.3) 8 (66.7) 1 (8.3) 5 (41.7)
PL-7 (n=27) 0 1 (3.7) 0 - 0 3 (11.1) 1 (3.7) 4 (14.8) 7 (25.9) 1 (3.7) 12 (44.4)
PL-12 (n=16) 0 2 (12.5) 1 (6.3) 0 - 2 (12.5) 1 (6.3) 3 (18.8) 0 0 10 (62.5)
SRP (n=141) 6 (4.3) 2 (1.4) 3 (2.1) 3 (2.1) 2 (1.4) - 2 (1.4) 8 (5.7) 22 (15.6) 3 (2.1) 52 (36.9)
Mi-2 (n=26) 4 (15.4) 1 (3.8) 2 (7.7) 1 (3.8) 1 (3.8) 2 (7.7) - 4 (15.4) 6 (23.1) 3 (11.5) 10 (38.5)
Ku (n=43) 1 (2.3) 2 (4.7) 1 (2.3) 4 (9.3) 3 (7.0) 8 (18.6) 4 (9.3) - 10 (23.3) 1 (2.3) 16 (37.2)
PM-Scl 75 (n=102) 6 (5.9) 2 (2.0) 8 (7.8) 7 (6.9) 0 22 (21.6) 6 (5.9) 10 (9.8) - 8 (7.8) 31 (30.4)
PM-Scl 100 (n=26) 1 (3.8) 1 (3.8) 1 (3.8) 1 (3.8) 0 3 (11.5) 3 (11.5) 1 (3.8) 8 (30.8) - 10 (38.5)
Ro52 (n=276) 36 (13.0) 12 (4.3) 5 (1.8) 12 (4.3) 10 (3.6) 52 (18.8) 10 (3.6) 16 (5.8) 31 (11.2) 10 (3.6) -

Figure 2

The intensity of myositis antibodies in the two groups of patients with or without co-occurred anti-Ro52 antibodies"

Figure 3

Association of band intensity between anti-Ro52 and anti-Jo-1, anti-SRP, and anti-PM-Scl 75"

[1] Cruellas MG, Viana VS, Levy-Neto M, et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis[J]. Clinics (Sao Paulo), 2013,68(7):909-914.
doi: 10.6061/clinics
[2] Lee A. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity[J]. Rheumatol Int, 2017,37(8):1323-1333.
doi: 10.1007/s00296-017-3718-1 pmid: 28417151
[3] Rutjes SA, Vree EW, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy[J]. Clin Exp Immunol, 1997,109(1):32-40.
doi: 10.1046/j.1365-2249.1997.4081308.x pmid: 9218821
[4] Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical review[J]. J Autoimmun, 2012,39(1/2):77-82.
doi: 10.1016/j.jaut.2012.01.014
[5] Damoiseaux J, Boesten K, Giesen J, et al. Evaluation of a novel line-blot immunoassay for the detection of antibodies to extractable nuclear antigens[J]. Ann N Y Acad Sci, 2005,1050:340-347.
doi: 10.1196/annals.1313.036 pmid: 16014550
[6] Frank MB, Mccubbin V, Trieu E, et al. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies[J]. J Autoimmun, 1999,12(2):137-142.
doi: 10.1006/jaut.1998.0265 pmid: 10047434
[7] Brouwer R, Hengstman GJ, Vree EW, et al. Autoantibody profiles in the sera of European patients with myositis[J]. Ann Rheum Dis, 2001,60(2):116-123.
doi: 10.1136/ard.60.2.116 pmid: 11156543
[8] Venables PJ. Antibodies to Jo-1 and Ro-52: why do they go together?[J]. Clin Exp Immunol, 1997,109(3):403-405.
doi: 10.1046/j.1365-2249.1997.4761369.x pmid: 9328112
[9] Bundell C, Rojana-Udomsart A, Mastaglia F, et al. Diagnostic performance of a commercial immunoblot assay for myositis antibody testing[J]. Pathology, 2016,48(4):363-366.
doi: 10.1016/j.pathol.2016.03.012 pmid: 27114370
[10] Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody[J]. Semin Arthritis Rheum, 2012,41(6):890-899.
doi: 10.1016/j.semarthrit.2011.09.008 pmid: 22078416
[11] 孟令超, 李毅, 张巍, 等. Jo-1综合征的临床及骨骼肌病理特点[J]. 中华医学杂志, 2016,96(29):2352-2355.
[12] Yamasaki Y, Satoh M, Mizushima M, et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52[J]. Mod Rheumatol, 2016,26(3):403-409.
doi: 10.3109/14397595.2015.1091155 pmid: 26344678
[13] Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response[J]. J Rheumatol, 2016,43(8):1566-1574.
doi: 10.3899/jrheum.150844 pmid: 27252419
[14] Ben-Chetrit E, Chan EK, Sullivan KF, et al. A 52-kD protein is a novel component of the SS-A/Ro antigenic particle[J]. J Exp Med, 1988,167(5):1560-1571.
doi: 10.1084/jem.167.5.1560 pmid: 3367095
[15] Peene I, Meheus L, de Keyser S, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease[J]. Ann Rheum Dis, 2002,61(10):929-933.
doi: 10.1136/ard.61.10.929 pmid: 12228166
[16] Menendez A, Gomez J, Escanlar E, et al. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: Diagnostic utility of their separate detection[J]. Autoimmunity, 2013,46(1):32-39.
pmid: 23039326
[17] Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis[J]. Rheumatol Int, 2016,36(7):935-943.
doi: 10.1007/s00296-016-3494-3 pmid: 27193471
[18] Gunnarsson R, El-Hage F, Aalokken TM, et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease[J]. Rheumatology (Oxford), 2016,55(1):103-108.
doi: 10.1093/rheumatology/kev300
[1] Zhengfang LI,Cainan LUO,Lijun WU,Xue WU,Xinyan MENG,Xiaomei CHEN,Yamei SHI,Yan ZHONG. Application value of anti-carbamylated protein antibody in the diagnosis of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 729-734.
[2] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[3] Yan-hong MENG,Yi-fan CHEN,Pei-ru ZHOU. Clinical and immunological features of primary Sjögren's syndrome patients with positive anti-centromere protein B antibody [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1088-1096.
[4] Lu ZHANG,Cheng CHEN,Mei-ting WENG,Ai-ping ZHENG,Mei-ling SU,Qing-wen WANG,Yue-ming CAI. Characteristics of serum autoantibodies in patients with lupus nephritis and tubulointerstitial damage [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1094-1098.
[5] Xiao-yan XING,Jun-xiao ZHANG,Feng-yun-zhi ZHU,Yi-fan WANG,Xin-yao ZHOU,Yu-hui LI. Clinical analysis of 5 cases of dermatomyositis complicated with macrophage activation syndrome [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1214-1218.
[6] Yi-cen YING,Qi TANG,Kai-wei YANG,Yue MI,Yu FAN,Wei YU,Yi SONG,Zhi-song HE,Li-qun ZHOU,Xue-song LI. Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(4): 644-651.
[7] ZHANG Pu-li,YANG Hong-xia,ZHANG Li-ning,GE Yong-peng,PENG Qing-lin,WANG Guo-chun,LU Xin. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1055-1060.
[8] LUO Lan,XING Xiao-yan,XIAO Yun-shu,CHEN Ke-yan,ZHU Feng-yun-zhi,ZHANG Xue-wu,LI Yu-hui. Clinical and immunological characteristics of patients with anti-synthetase syndrome complicated with cardiac involvement [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1078-1082.
[9] XIAO Yun-shu,ZHU Feng-yun-zhi,LUO Lan,XING Xiao-yan,LI Yu-hui,ZHANG Xue-wu,SHEN Dan-hua. Clinical and immunological characteristics of 88 cases of overlap myositis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1088-1093.
[10] YI Wen-xia,WEI Cui-jie,WU Ye,BAO Xin-hua,XIONG Hui,CHANG Xing-zhi. Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1191-1195.
[11] Feng-yun-zhi ZHU,Xiao-yan XING,Xiao-fei TANG,Yi-min LI,Miao SHAO,Xue-Wu ZHANG,Yu-hui LI,Xiao-lin SUN,Jing HE. Clinical and immunological characteristics of myositis complicated with thromboembolism [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 995-1000.
[12] Jing ZHAO,Feng SUN,Yun LI,Xiao-zhen ZHAO,Dan XU,Ying-ni LI,Yu-hui LI,Xiao-lin SUN. Significance of anti-tubulin-α-1C autoantibody in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1009-1013.
[13] Yu-zhou GAN,Yu-hui LI,Li-hua ZHANG,Lin MA,Wen-wen HE,Yue-bo JIN,Yuan AN,Zhan-guo LI,Hua YE. Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1001-1008.
[14] Jiao-niu DUAN,Wei DU,Rui-hong HOU,Ke XU,Gai-lian ZHANG,Li-yun ZHANG. Progressive necrosis of lipid: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1182-1184.
[15] Jing XU,Jing XU,He LI,Jie TANG,Jian-long SHU,Jing ZHANG,Lian-jie SHI,Sheng-guang LI. Dermatomyositis combined with IgA vasculitis: A case report [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1173-1177.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd